Histiocytic and Dendritic Cell Neoplasm clinical trials at UCSF
2 in progress, 1 open to eligible people
Histiocytic and dendritic cell neoplasm is a type of cancer. UCSF is conducting a clinical trial to study a new treatment called Selpercatinib. This trial is for people with advanced tumors, lymphomas, or histiocytic disorders that have a gene alteration called activating RET. There is one more trial in progress, but it is not accepting new participants at this time.
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
open to eligible people ages 12 months to 21 years
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.
Oakland, California and other locations
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Sorry, in progress, not accepting new patients
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.
Oakland, California and other locations
Our lead scientists for Histiocytic and Dendritic Cell Neoplasm research studies include Carla B. Golden Arun A. Rangaswami.
Last updated: